WO2008081013A1 - Utilisation d'analogues de la somatostatine dans une céphalée vasculaire de horton - Google Patents

Utilisation d'analogues de la somatostatine dans une céphalée vasculaire de horton Download PDF

Info

Publication number
WO2008081013A1
WO2008081013A1 PCT/EP2008/050006 EP2008050006W WO2008081013A1 WO 2008081013 A1 WO2008081013 A1 WO 2008081013A1 EP 2008050006 W EP2008050006 W EP 2008050006W WO 2008081013 A1 WO2008081013 A1 WO 2008081013A1
Authority
WO
WIPO (PCT)
Prior art keywords
somatostatin
analog
cluster headache
srif
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2008/050006
Other languages
English (en)
Inventor
Herbert Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to CA002674186A priority Critical patent/CA2674186A1/fr
Priority to MX2009007188A priority patent/MX2009007188A/es
Priority to US12/521,191 priority patent/US20100069296A1/en
Priority to EP08701194A priority patent/EP2114439A1/fr
Priority to AU2008203708A priority patent/AU2008203708B2/en
Priority to BRPI0806484-9A priority patent/BRPI0806484A2/pt
Publication of WO2008081013A1 publication Critical patent/WO2008081013A1/fr
Priority to US13/226,837 priority patent/US20110319329A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a new use of Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs).
  • SRIF Somatostatin peptidomimetics
  • Somatostatin is a tetradecapeptide having the structure
  • the somatostatin class is a known class of small peptides comprising the naturally occurring somatostatin-14 and analogues having somatostatin related activity, e.g. as disclosed by A.S. Dutta in Small Peptides, Vol.19, Elsevier (1993).
  • somatostatin analog as used herein is meant any straight-chain or cyclic polypeptide having a structure based on that of the naturally occurring somatostatin-14 wherein one or more amino acid units have been omitted and/or replaced by one or more other amino radical(s) and/or wherein one or more functional groups have been replaced by one or more other functional groups and/or one or more groups have been replaced by one or several other isosteric groups.
  • the term covers all modified derivatives of the native somatostatin-14 which exhibit a somatostatin related activity, e.g. they bind to at least one of the five somatostatin receptor (SSTR), preferably in the nMolar range.
  • SSTR five somatostatin receptor
  • Natural somatostatin binds and activates all 5 somatostatin receptors (SSTR1-5) with nmol efficacy and thus causes its multiple physiological effects.
  • Synthetically available somatostatin analogs differ in their binding affinity to the different somatostatin receptor subtypes and often bind selectively to one or few subtypes with significantly higher affinity.
  • Somatostatin analogs of particular interest according to the present invention have a high binding affinity to human SSTR1 ,2,3,5 and have been described e.g. in WO 97/01579, the contents of which being incorporated herein by reference.
  • Said somatostatin analogs comprise the amino acid sequence of formula I -(0/L)TrP-LyS-X 1 -X 2 -
  • X 1 is a radical of formula (a) or (b)
  • R 1 is optionally substituted phenyl, wherein the substituent may be halogen, methyl, ethyl, methoxy or ethoxy,
  • R 2 IS -Z 1 -CH 2 -R 11 -CH 2 -CO-O-CH 2 -RI , — ⁇ ⁇ O ⁇ or
  • Z 1 is O or S
  • X 2 is an ⁇ -amino acid having an aromatic residue on the C ⁇ side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His,(Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys 9 of the native somato- statin-14.
  • Somatostatin analogs of particular interest which have a high binding affinity to human SSTR1 ,2,3,5 have also been described e.g. in WO02/10192, the contents of which being incorporated herein by reference.
  • Said somatostatin analogs comprise the compound of formula
  • pasireotide or a pharmaceutically acceptable salt thereof.
  • CH Cluster headache
  • Injectable and intranasal sumatriptan are highly effective with a rapid onset of action, are portable, and have no tachyphylaxis even with frequent use in prolonged cluster bouts.
  • the drawbacks of sumatriptan include the need for an injection with the subcutaneous formulation, the limitation of the number of daily doses that can be administered, the incidence of adverse effects especially with the subcutaneous formulation, and the considerable cost of each dose.
  • Oral zolmitriptan has been demonstrated to be of only modest efficacy in acute episodic cluster headache at relatively high dose when compared with its use in migraine, thereby rendering it of limited utility in clinical practice.
  • Intranasal dihydroergotamine has been reported to be better than placebo, but the time to onset of response was not defined and the study used pre-lntemational Headache S ociety (IHS) diagnostic criteria.
  • IHS Headache S ociety
  • ergots and triptans are contraindicated in patients with vascular disease. Caution must be exercised in patients with CH, because the disorder predominates in middle-aged men, who often have risk factors for cardiovascular disease, particularly smoking.
  • Octreotide a octapeptide somatostatin analog with a longer half-life of approximately 1.5 hours, can be given subcutaneously, and has been studied as an abortive agent for the acute treatment of CH (M. S. Matharu et al., Ann Neurol. 2004; 56; 488-494).
  • octreotide is a relatively large molecule (consisting of 8 amino acids) which preferentially binds to SSTR2 and, only to a lesser extent, to SSTR3 and SSTR5. Therefore, the efficacy of the octreotide treatment of CH is only limited.
  • the present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1 ,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache.
  • SRIF Somatostatin
  • SRIF-analog with a high binding affinity to human SSTR1 ,2,3,5" as used herein refers to compounds which have a high binding affinity to SSTR1 , SSTR2, SSTR3 and SSTR5, preferentially an IC50 ⁇ 10 nmol/l at SSTR1 and SSTR2 and an IC50 ⁇ 3 nmol/l at SSTR3 and SSTR5; (Schmid et al., Neuroendocrinol. 2004;80:47-50).
  • An especially preferred COMPOUND OF THE INVENTION is pasireotide or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of treating cluster headache in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a COMPOUND OF THE INVENTION or a pharmaceutically acceptable salt thereof.
  • the present invention relates also to a pharmaceutical composition for treatment of cluster headache, comprising a therapeutically effective amount of a COMPOUND OF THE INVENTION or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable diluents or carriers.
  • the present invention relates also to a commercial package comprising a COMPOUND OF THE INVENTION together with instructions for use thereof in the treatment of cluster headache.
  • compositions for the treatment of cluster headache comprise an effective amount of the Somatostatin analog in free base form or in pharmaceutically acceptable salt form together with one or more pharmaceutically acceptable diluent or carrier.
  • Such compositions may be formulated in conventional manner.
  • Somatostatin analogs may also be administered in sustained release form, e.g. in the form of implants, microcapsules, microspheres or nanospheres comprising e.g. a biodegradable polymer or copolymer, in the form of a liposomal formulation, or in the form of an autogel, e.g. a solid or semi-solid composition capable of forming a gel after interaction with patient's body fluids.
  • the COMPOUNDS OF THE INVENTION can, for example, be formulated as disclosed in WO05/046645 (especially pasireotide).
  • COMPOUNDS OF THE INVENTION or a pharmaceutically acceptable salt thereof may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or suspensions (including e.g. the sustained release form as indicated above), orally using a conventional absorption enhancer if necessary, in a nasal or a suppository form or topically, e.g. in the form of an ophthalmic liquid, gel, ointment or suspension preparation, e.g. a liposomal, microsphere or nanosphere formulation, e.g. for instillation or subconjunctival or intra- or peri-ocular injections.
  • parenterally e.g. in form of injectable solutions or suspensions (including e.g. the sustained release form as indicated above), orally using a conventional absorption enhancer if necessary, in a nasal or a suppository form or topically, e.g. in the form of an ophthalmic liquid, gel, ointment or suspension preparation,
  • compositions are prepared in a manner known per se, and comprise approximately from 1 % to 100 %, preferentially from approximately 1 % to 40 %, especially from approximately 20 % to 30 %, active ingredient.
  • references to the active ingredients are meant to also include the pharmaceutically acceptable salts. If these active ingredients have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
  • the active ingredients having an acid group (for example COOH) can also form salts with bases. Salts include acid addition salts with e.g. inorganic acids, polymeric acids or organic acids, for example with hydrochloric acid, acetic acid, lactic acid, aspartic acid, benzoic acid, succinic acid or pamoic acid. Acid addition salts may exist as mono- or divalent salts, e.g.
  • Preferred salts are tha lactate, aspartate, benzoate, succi- nate and pamoate including mono- and disalts, more preferably the aspartate di-salt and the pamoate monosalt, e.g. of pasireotide.
  • the active ingredient or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or include other solvents used for crystallization.
  • the pharmacological activity of a COMPOUND OF THE INVENTION in cluster headache may, for example, also be demonstrated in clinical studies. Such clinical studies are preferably randomized, double-blind, clinical studies in patients suffering from cluster headache.
  • the effective dosage of the active ingredients employed may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the severity of the condition being treated. Thus, the dosage regimen is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, ameliorate or arrest the progress of the condition. Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of the active ingredients.

Abstract

La présente invention porte sur l'utilisation d'un analogue de la Somatostatine (SRIF) qui a une haute affinité de liaison à STRR1,2,3,5 humain, ou d'un sel pharmaceutiquement acceptable de celui-ci pour la préparation d'une composition pharmaceutique pour le traitement d'une céphalée vasculaire de Horton.
PCT/EP2008/050006 2007-01-02 2008-01-02 Utilisation d'analogues de la somatostatine dans une céphalée vasculaire de horton WO2008081013A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002674186A CA2674186A1 (fr) 2007-01-02 2008-01-02 Utilisation d'analogues de la somatostatine dans une cephalee vasculaire de horton
MX2009007188A MX2009007188A (es) 2007-01-02 2008-01-02 Uso de analogos de somatostatina en cefalalgia histaminica.
US12/521,191 US20100069296A1 (en) 2007-01-02 2008-01-02 Use of somatostatin analogs in cluster headache
EP08701194A EP2114439A1 (fr) 2007-01-02 2008-01-02 Utilisation d'analogues de la somatostatine dans une céphalée vasculaire de horton
AU2008203708A AU2008203708B2 (en) 2007-01-02 2008-01-02 Use of somatostatin analogs in cluster headache
BRPI0806484-9A BRPI0806484A2 (pt) 2007-01-02 2008-01-02 uso de análogos de somatostatina em cefaléia em salvas
US13/226,837 US20110319329A1 (en) 2007-01-02 2011-09-07 Use of somatostatin analogs in cluster headache

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100010A EP1941902A1 (fr) 2007-01-02 2007-01-02 Utilisation d' analogues de somatostatin pour le traitment de chéphalée vasculaire de horton
EP07100010.3 2007-01-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/226,837 Continuation US20110319329A1 (en) 2007-01-02 2011-09-07 Use of somatostatin analogs in cluster headache

Publications (1)

Publication Number Publication Date
WO2008081013A1 true WO2008081013A1 (fr) 2008-07-10

Family

ID=37846227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050006 WO2008081013A1 (fr) 2007-01-02 2008-01-02 Utilisation d'analogues de la somatostatine dans une céphalée vasculaire de horton

Country Status (8)

Country Link
US (2) US20100069296A1 (fr)
EP (2) EP1941902A1 (fr)
AU (1) AU2008203708B2 (fr)
BR (1) BRPI0806484A2 (fr)
CA (1) CA2674186A1 (fr)
MX (1) MX2009007188A (fr)
RU (1) RU2009129597A (fr)
WO (1) WO2008081013A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107522779A (zh) * 2011-09-04 2017-12-29 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017037A1 (fr) * 1992-02-21 1993-09-02 Sandoz Ltd. Traitement des crises aigues de migraine et de cephalee vasculaire de horton
WO1997001579A2 (fr) * 1995-06-29 1997-01-16 Novartis Ag Peptides de somatostatine
WO2002010192A2 (fr) * 2000-08-01 2002-02-07 Novartis Ag Analogues de somatostatine
WO2005041901A2 (fr) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017037A1 (fr) * 1992-02-21 1993-09-02 Sandoz Ltd. Traitement des crises aigues de migraine et de cephalee vasculaire de horton
WO1997001579A2 (fr) * 1995-06-29 1997-01-16 Novartis Ag Peptides de somatostatine
WO2002010192A2 (fr) * 2000-08-01 2002-02-07 Novartis Ag Analogues de somatostatine
WO2005041901A2 (fr) * 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. S. MATHARU ET AL., ANN NEUROL,, vol. 56, 2004, pages 488 - 494, XP002426584 *
See also references of EP2114439A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107522779A (zh) * 2011-09-04 2017-12-29 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物
CN107522779B (zh) * 2011-09-04 2021-10-26 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物

Also Published As

Publication number Publication date
AU2008203708B2 (en) 2011-12-01
BRPI0806484A2 (pt) 2011-09-27
RU2009129597A (ru) 2011-02-10
US20110319329A1 (en) 2011-12-29
EP1941902A1 (fr) 2008-07-09
US20100069296A1 (en) 2010-03-18
MX2009007188A (es) 2009-07-14
CA2674186A1 (fr) 2008-07-10
AU2008203708A1 (en) 2008-07-10
EP2114439A1 (fr) 2009-11-11

Similar Documents

Publication Publication Date Title
JP3255289B2 (ja) アルファー―２―アドレナリン作動薬及び成長ホルモン放出ペプチドによる肥満症の治療
Paran et al. Octreotide treatment in patients with severe acute pancreatitis
US7485620B2 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
US9149510B2 (en) Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
JP5721624B2 (ja) 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
US20110319329A1 (en) Use of somatostatin analogs in cluster headache
EP2224947B1 (fr) Utilisation d'analogues de somatostatine dans le méningiome
MX2008010141A (en) Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701194

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008203708

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2008701194

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008701194

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12521191

Country of ref document: US

Ref document number: 4223/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2674186

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/007188

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008203708

Country of ref document: AU

Date of ref document: 20080102

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009129597

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0806484

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090702